A Phase I, Open-label, Randomized, Two Way Crossover Pharmacokinetic Study Comparing the Bioavailability of Acetylsalicylic Acid (ASA) After 5 Days Repeated Once Daily Administration of a Fixed Dose Combination Capsule of ASA 81 mg/Esomeprazole 20 mg and ASA 80 mg (European Aspirin Reference Product).

Trial Profile

A Phase I, Open-label, Randomized, Two Way Crossover Pharmacokinetic Study Comparing the Bioavailability of Acetylsalicylic Acid (ASA) After 5 Days Repeated Once Daily Administration of a Fixed Dose Combination Capsule of ASA 81 mg/Esomeprazole 20 mg and ASA 80 mg (European Aspirin Reference Product).

Completed
Phase of Trial: Phase I

Latest Information Update: 09 May 2012

At a glance

  • Drugs Aspirin; Aspirin/esomeprazole
  • Indications Cardiovascular disorders; Embolism and thrombosis; NSAID-induced gastrointestinal damage
  • Focus Pharmacokinetics
  • Most Recent Events

    • 09 May 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 20 Apr 2012 Status changed from suspended to recruiting as reported by ClinicalTrials.gov.
    • 28 Mar 2012 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top